Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Janssen to present growing set of oncology data at the 2016 European Society for Medical Oncology (ESMO) Congress

Posted on: 29 Sep 16

BEERSE, Belgium--(BUSINESS WIRE)--Janssen-Cilag International NV today announced data from ten company-sponsored abstracts will be presented at the 2016 ESMO Congress in Copenhagen, Denmark, on the 9th and 10th October 2016. The data feature four Janssen medicines spanning multiple disease areas including prostate, urothelial and blood cancer, and showcase Janssen’s broad portfolio in oncology and commitment to patients.

“The data to be presented at ESMO highlights the efficacy and safety profiles of Janssen treatments and also provides insights from a large, real-world prostate cancer patient population on how patients live with, and manage, their disease. Every patient with cancer will face his or her own unique journey and we are committed to helping redefine that journey. We hope that these findings will help us improve outcomes for cancer patients in the future,” said Jane Griffiths, Company Group Chairman, Janssen European, Middle East and Africa (EMEA).

Among the abstracts selected for presentation is data from the Prostate Cancer Registry, the first and largest prospective study of European patients with metastatic castration-resistant prostate cancer (mCRPC).

Also in prostate cancer, a follow-up analysis from the COU-AA-302 study, investigating long-term safety of ZYTIGA® (abiraterone acetate) for the treatment of mCRPC, will be presented. In addition, the design of the TITAN and ATLAS trials will be presented; the trials will study the efficacy and safety profiles of apalutamide, a new generation androgen receptor inhibitor, in patients with newly-diagnosed mCRPC.

In bladder cancer, Phase 1 data will be presented around urothelial carcinoma (UC) examining the safety, efficacy and tolerability in patients treated with the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib.

Haematological malignancy data to be featured includes results from the Phase 3 CASTOR study, evaluating DARZALEX® (daratumumab) in combination with bortezomib and dexamethasone, compared to bortezomib and dexamethasone alone in patients with multiple myeloma who received one or more prior lines of therapy. This study has been published in the New England Journal of Medicine and formed the basis for recent submissions to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), seeking to expand existing licenses for DARZALEX.1

The following Janssen abstracts have been accepted for presentation at the 2016 ESMO congress:

Haematological Malignancies, Proffered Paper Session, 9th October, 11:00-12:00 CEST (Bern):

11:00-11:15: 906O - Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR2

Poster Display, 9th October, 13:00 – 14:00 CEST (Copenhagen, Hall E):

13:00-14:00: 738P - Meta-analysis of randomized clinical trials in metastatic castration resistant prostate cancer: Comparison of hypertension, neurological and psychiatric adverse events on enzalutamide and abiraterone acetate plus prednisone treatment3

13:00-14:00: 740P - Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA+ P) for ≥ 4 years (yrs)4

13:00-14:00: 746P - The prostate cancer registry: Patient characteristics, treatments and preliminary outcomes from a large observational study of metastatic castration-resistant prostate cancer (mCRPC)5

13:00-14:00: 769 Trial in Progress (TiP) - ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy6

13:00-14:00: 771TiP - TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)7

13:00-14:00: 789P - Pharmacokinetics (PK) of the pan-FGFR inhibitor erdafitinib in urothelial carcinoma8

13:00-14:00: 845TiP - Ongoing phase 2 study of erdafitinib (JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (M/UR UC) and FGFR gene alterations9

Genitourinary Tumours Non-Prostate, Poster Discussion Session, 9th October, 16:30-17:30 CEST (Athens):

17:10-17:30: 781PD - Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma10

Poster Display, 10th October, 13:00 – 14:00 CEST (Copenhagen, Hall E):

13:00-14:00: 1161P - Utility of a targeted NGS oncology assay for circulating tumor DNA in a multi-histology clinical setting11

Please note that all abstracts accepted for presentation at the ESMO congress are subject to the organisers’ embargo policies.

For more information:

Editor's Details

Mike Wood

Last updated on: 29/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.